Skip to main content
Premium Trial:

Request an Annual Quote

Nasdaq Set to Delist Valentis Stock for Low Market Cap; Firm to Appeal

NEW YORK, Aug. 28 - Valentis today said the Nasdaq exchange has threatened to delist its stock for failing to hold its market capitalization above $50 million.

 

Valentis said it received a letter from the Nasdaq on Aug. 22 that said the stock will be delisted from the exchange on Aug. 30 unless the company requests an appeal hearing.Valentis said it requested a hearing and will appear before a Nasdaq listing-qualifications panel to discuss how it plans to set itself straight. The meeting will likely take place within 45 days.

 

The company, maker of the GeneMedicine and GeneSwitch DNA vaccine platforms, stressed that obtaining a hearing does not guarantee a stay of delisting.

 

Shares in Valentis closed down $.14 at $.60 yesterday. Valentis' market cap is $21.0 million.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.